[{"orgOrder":0,"company":"StrideBio","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"StrideBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StrideBio \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"StrideBio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"STRX-310","moa":"AChE","graph1":"Neurology","graph2":"Discovery","graph3":"StrideBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StrideBio \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio \/ Northpond Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by StrideBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ACS GCI
                          Not Confirmed
                          ACS GCI
                          Not Confirmed

                          Details : The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 04, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery

                          Sponsor : Ginkgo Bioworks

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          ACS GCI
                          Not Confirmed
                          ACS GCI
                          Not Confirmed

                          Details : Proceeds to advance structure-guided AAV capsid engineering platform and pipeline of novel gene therapy candidates into the clinic, including four new wholly-owned programs.

                          Product Name : STRX-310

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 16, 2021

                          Lead Product(s) : STRX-310

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Northpond Ventures

                          Deal Size : $81.5 million

                          Deal Type : Series B Financing

                          blank